Litigation Intel

Oxbryta Withdrawal

Pfizer withdrew sickle cell drug Oxbryta after data showed increased pain crises and deaths, prompting injury claims.

Composite score

Scored Oct 26, 8:02 AM

Oxbryta litigation is in an early phase characterized by active intake campaigns following the manufacturer's global withdrawal over mortality data.

Score breakdown

Four dimensions, each 0-100, generated by AI from the recent signal feed plus general knowledge of the tort.

Momentum72

Global market withdrawal and regulatory alerts generate strong attention, with law firms actively reviewing injury and wrongful death claims.

Science82

Clinical trial data showing an imbalance in fatal events and vaso-occlusive crises directly prompted the voluntary worldwide market withdrawal.

Campaign70

Plaintiff law firms launched targeted marketing campaigns and digital intake funnels following the sudden removal of the drug.

Litigation stage20

The litigation is in early filing and case investigation stages, with individual actions emerging after the recent withdrawal.

Scores are generated by AI from public sources for market research. They are not legal advice or a prediction of any outcome.

We can launch an exclusive campaign to your intake criteria within one week.

8 recent signals across news, FDA, PubMed, and court sources.